Caretek Medical
www.caretekmedical.net
seis eis
Investment to date:
£3,985
Share price:
£3.60

target amount:
£130,000
£50,000
Caretek Medical
Caretek Medical is developing an app for smartphones which will be a self-learning AI system, with cloud-based infrastructure. The team includes globally recognised clinical experts in maternity care, who are developing a digital assistant to help pregnant women access information tailored to the individual characteristics of their pregnancy - ‘a pocket expert midwife/obstetrician’
About Caretek Medical

Background

In 1960, Norman Morris, an academic and humanitarian, wrote a landmark paper in the Lancet, which proposed a revolution in attitudes within the maternity services. He was highly critical of the lack of care and empathy which prevailed at that time.

He wrote ‘Midwives and Obstetricians have an especial responsibility, for they are there at the beginning, and probably it is the manner of the beginning that matters most of all’.

Philip Steer, his successor as Professor when the Charing Cross Hospital Medical School became the Charing Cross and Westminster Medical School (now part of the Imperial College Faculty of Medicine) has joined Norman’s son (also an obstetrician and gynaecologist) Nick Morris, and technology expert Terry Hook, to plan a ‘Digital Doula*’ to help support and empower pregnant women.

Together with associates, they have formed Caretek medical to develop the ‘Digital Doula’, a smartphone app, which is the subject of this funding appeal. The Caretek Medical Board is chaired by Sir Sabaratnam Arulkumaran, past president of both the Royal College of Obstetricians and Gynaecologists in the UK and FIGO, the International Federation of Gynaecology and Obstetrics.

Image of APP

 

The time is right for the Doula 

Caretek Medical is creating a platform to meet the needs of both mothers and healthcare professionals. The Caretek app will give mothers access to healthcare guidelines specifically tailored to their individual characteristics, in an easily understandable format. A summary of risk factors identified will also be available for clinicians (midwives and obstetricians). The app will enable mothers to take personal ownership of their pregnancy data, and at the same time prompt healthcare professionals to follow national/international clinical guidelines. The platform will be self-learning, comprising an App, AI, and cloud-based infrastructure.

The Caretek Medical pregnancy app will revolutionise the delivery of safe, effective and individualised maternity care by empowering and motivating the mothers to maximise their chances of a successful pregnancy. The development of the Caretek Medical app is being supported by senior staff of both the Women’s Health Academic Centre at St Thomas’ Hospital, part of King’s College London (Head of Department, Professor Lucilla Poston CBE) and the Academic Department of obstetrics and gynaecology at the Chelsea and Westminster Hospital, part of Imperial College London (Head of Department, Prof Mark Johnson).

Professor Philip Steer, emeritus Professor at Imperial College London, directs the development of the medical algorithms underlying the app and founder Dr Nicholas Morris directs the maternal interface.

CEO Terry Hook leads the business team of Garry Hirth, Damon Clark, Bryan Foss and others developing the commercial and technology aspects of the business.  

The Problem

For most women, pregnancy is a wonderful experience, but sometimes pregnancy does not progress according to plan. When this happens, women need immediate and factually correct information relevant to what is going on, and whether anything needs to be done about it. Often, reassurance is all that is needed, but occasionally urgent action is necessary and life-saving.

Busy obstetricians and midwives often have insufficient time to deal with such issues promptly, and failures in care are contributing to a growing litigation crisis. In the UK in 2017-18 more than a billion and half pounds was paid out in compensation for errors in maternity care, indicating the scale of the problem.

The Solution

The App and Platform are mother focused, rather than focused primarily on health professionals. It will encourage women not only to store their own pregnancy data but also to compare their progress and care with national and international standards. Key aspects that will be monitored include maternal blood pressure, weight, glucose testing (diabetes), as well as fetal growth and wellbeing. With the mother's permission, the clinician can access (either online or via the App) a dashboard presenting the current risk indicators and an audit trail of information relating to the pregnant woman.

The architecture of the platform allows for the collection of accurate data directly from the user. The algorithms which underline the analysis and interpretation of the data, are unique and result from over 30 years' experience of maternity data collection. The IP will continue to grow as data repositories enable further refinement and addition of algorithms. The IP belongs to Caretek Medical.

Image of app 2

The Markets

The markets are global, with an estimation of 141 million births worldwide in 2015- these are 386,000 births every day according to Our Wold in Data and 847k conceptions in 2017 in England and Wales alone according to the Office for National Statistics.

We are currently negotiating to be on approved supplier lists and will negotiate commercial arrangements for licensing the use of our IP.

Market Strategy

Our marketing strategy for promoting the app is initially based on social media outreach, digital marketing, distribution through academic and supporting networks for expectant mothers and word of mouth. We intend targeting networks for pregnant women (e.g. mumsnet) and women who are planning to become pregnant (‘pre-conception’). We have planned a program to access ‘end users’ based on partnership with distributors and manufacturers of both maternity and childcare products. In addition, we have a traditional B2B sales plan for commercial organizations, medical providers and Academia.




To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below

Join
Log in


Why join Crowd for Angels?

arrowRegister in minutes

arrowNo fees for Investors

arrowInvest from £25

arrowShares held through a Nominee

Why invest in UK businesses

Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain higher interest rates than available on bank deposits.


About Crowd for Angels

Crowd for Angels is a regulated crowdfunding platform that raises funds for companies through the issue of shares (equity) and crowd bonds (debt) to investors. Our goal is to bring innovative and appealing products to investors and to provide funding for companies throughout their growth cycle.

Offer Information
Min Max
Investment Target £50,000 £130,000
Share Price £3.60 £3.60
Shares Offered info 13,889 36,111
Percentage Offered info 4.10% 10.00%
Shares Issued info 325,000
Pre-money Valuation 1,170,000
Share Type Ordinary
Minimum Investment £54.00
Tax Relief Available SEIS & EIS
Sector Consumer Goods
Healthcare & Pharmaceuticals
Internet, Apps & eCommerce
Location London, United Kingdom
Company Number 10154317
Pitch Launched On 03/06/2019
Pitch Closes On 16/09/2019
Accepted Payment Methods
Payment Methods

To read the full Caretek Medical pitch, please join.
It is free, quick and easy.

Join Now

Already registered? Log in

Risk Warning

Investing in small public listed or private companies involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Investing in debt pitches through Crowd for Angels (UK) Limited involves lending to companies and therefore your capital is at risk and interest payments are not guaranteed if the borrower defaults. Crowd for Angels is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own Investment Decisions. You will only be able to invest via Crowd for Angels once you are authorised. Please click here to read the full Risk Warning.

This page has been approved as a Financial Promotion by Crowd for Angels (UK) Limited (Company number: 03064807) , which is authorised and regulated by the Financial Conduct Authority (Reference number: 176508). Investments can only be made on the basis of information provided in the Pitches by the Investee Companies concerned. Crowd for Angels takes no responsibility for this Information or for any recommendations or opinions made by the Investee Companies.

Pitches may contain forward looking statements and financial forecasts or projections. Forecasts are not a reliable indicator of future performance. Crowd For Angels makes no judgement or opinion of the likelihood of targets being achieved. Investments made in companies listed on the Crowd For Angels platform are not covered by the Financial Services Compensation Scheme (FSCS).

The availability of any tax relief, including EIS and SEIS, depends on the individual circumstances of each investor and of the company concerned, and may be subject to change in the future. If you are in any doubt about the availability of any tax reliefs, or the tax treatment of your investment, you should obtain independent tax advice before proceeding with your investment.